유전자 재조합 Erythropoietin (LB-00014) 의 일반약리작용 = General Pharmacology of Recombinant Erythropoietin (LB-00014)

다국어 초록 (Multilingual Abstract)

General pharmacological properties of LB-00014, an erythropoietin which was produced by recombinant DNA technique in Biotech Research Institute, LG Chemical Ltd. were examined. The administration of LB-00014 (60, 600, 6000 IU/㎏, iv) in mice had no effect in general behavior and central nervous system, and no influences on normal body temperature, writhing syndromes induced by 0.7% acetic acid solution and chemoshock produced by strychnine and pentetrazole solution. LB-00014 (60, 600, 6000 IU/㎏, iv) given to anesthetized rabbits showed no effect on blood pressure of carotid artery and respiration rates, and it did not influence the responses produced by injection of acetylcholine or epinephrne. The administration of LB-00014 (601, 600, 6000 IU/㎏, iv) in rats had no effect on the plasma prothrombin time, activated partial thromboplastin time and hemolytic action. The platelet aggregation induced by collagen in human plasma was not influenced by LB-00014 (10, 100, 1000 IU/㎏, iv). It showed no direct effect at 100 and 1000IU/ml in isolated stomach fundus and uterus of rats and ileum of guinea-pig, and it also had no inhibition of contraction produced by acetylcholine, oxytocin, serotonin and histamine in the above-mentioned preparations. It did not influence gastric secretion, pH and acid output at 6000 IU/㎏, iv in rats, but showed a significant increase in intestinal propulsion of mice at 6000 IU/㎏, iv. Its administration (60, 600, 6000 IU/㎏, iv) caused no effect on urine and electrolyte excretion in rats. These results indicate that LB-00014 does not exsert any of serious pharmacological effects.